{"nctId":"NCT00129402","briefTitle":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","startDateStruct":{"date":"2005-08"},"conditions":["Hypercholesterolemia"],"count":248,"armGroups":[{"label":"Pooled subjects who received ezetimibe with simvastatin","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe with simvastatin"]},{"label":"Pooled subjects who received simvastatin monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: simvastatin"]}],"interventions":[{"name":"ezetimibe with simvastatin","otherNames":[]},{"name":"simvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adolescent (ages 10 - 17 years) boys or girls weighing at least 88 lbs (40 kg).\n* Subjects must have high cholesterol (low density lipoprotein cholesterol \\[LDL-C\\] more than 159 mg/dL or 4.1 mmol/L) and a family history of high cholesterol.\n\nExclusion Criteria:\n\n* Subjects diagnosed with delayed puberty.\n* Subjects who are sensitive to simvastatin and/or ezetimibe.\n* Subjects who drink alcohol excessively or who have a history of alcohol or drug abuse within the past 2 years.\n* Subjects who are known to be HIV positive, are undergoing LDL apheresis or plasma apheresis, or have had a partial ileal bypass.","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","description":"Least squares mean percent change from Baseline in LDL-C at the end of Step 1 (Week 6) in the pooled groups who received ezetimibe plus simvastatin compared with pooled groups who received simvastatin monotherapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.45","spread":"1.19"},{"groupId":"OG001","value":"-34.43","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.23","spread":".96"},{"groupId":"OG001","value":"-26.28","spread":".99"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.84","spread":"1.13"},{"groupId":"OG001","value":"-32.68","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.56","spread":"30.26"},{"groupId":"OG001","value":"-12.28","spread":"31.49"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.92","spread":"1.1"},{"groupId":"OG001","value":"-26.69","spread":"1.11"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","spread":"1.16"},{"groupId":"OG001","value":"6.47","spread":"1.19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":126},"commonTop":["Nasopharyngitis","Headache","Influenza","Cough","Acne"]}}}